Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. 

LONDON, March 31, 2025 /PRNewswire/ — Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor, Alphabet.

Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities. 

“We’re excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach,” said Isomorphic Labs founder and CEO, Sir Demis Hassabis. “This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.” 

Since its founding, the company has developed a number of next-generation AI models that come together to form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. One example breakthrough model is AlphaFold 3, developed and released in May 2024 by Isomorphic Labs together with Google DeepMind, with the ability to accurately predict the structure and interactions of all of life’s molecules. Leveraging these state-of-the-art AI technologies, Isomorphic Labs has established a drug discovery portfolio consisting of partnered programs with pharmaceutical industry leaders Eli Lilly and Novartis, as well as internal programs primarily focused in oncology and immunology. Novartis and Isomorphic Labs recently expanded the scope of their original collaboration just over a year after initiating the relationship. 

“At Thrive, we aim to invest in category-defining companies with singular conviction, and that has led us to Isomorphic Labs,” said Joshua Kushner, Founder and CEO of Thrive Capital. “We believe Isomorphic has earned a rare position to define a new age of drug discovery and design, and we are deeply inspired by their mission and the extraordinary progress they have made to date.” 

The investment will accelerate Isomorphic Labs’ frontier AI research and development, to rapidly advance the company’s next-generation AI drug design engine. Isomorphic Labs will consequently be expanding its team of world-class talent as part of its next phase of growth. 

“AI and machine learning have long held the promise of transforming drug discovery, yet few companies over the past decade have unlocked their full potential. After witnessing the extraordinary pace of innovation at Isomorphic Labs, we believe their pioneering approach will redefine AI-powered drug discovery,” said Dr. Krishna Yeshwant, Managing Partner at GV. “With Sir Demis Hassabis at the helm, Isomorphic has assembled an exceptional team at the intersection of life sciences and technology. We’re proud to support them as they advance the development of new treatments for patients.” 

ABOUT ISOMORPHIC LABS 

Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by AI pioneer Sir Demis Hassabis, and its founding was built on the Nobel-winning AI breakthrough, AlphaFold. Isomorphic Labs, together with Google DeepMind, developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life’s molecules with unprecedented accuracy. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has an office in Lausanne, Switzerland. 

Advertisement

Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. 

For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X. 

View original content:https://www.prnewswire.co.uk/news-releases/isomorphic-labs-announces-600-million-funding-to-further-develop-its-next-generation-ai-drug-design-engine-and-advance-therapeutic-programs-into-the-clinic-302415534.html

Sapiens’ solutions accelerate insurer’s seamless, data-driven digital transformation

ROCHELLE PARK, N.J., March 31, 2025 /PRNewswire/ — Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced that a major U.S. multi-line insurer has expanded its partnership with Sapiens by selecting Sapiens Insurance Platform for Life & Annuities, which includes Sapiens CoreSuite for Life & Annuities, Sapiens DataSuite, and Sapiens Cloud Services.

The insurer’s life business has been supported by Sapiens UnderwritingPro for nearly a decade, and the implementation of Sapiens Insurance Platform will further accelerate their digital transformation. With CoreSuite’s robust, high-performing APIs, the insurer will seamlessly integrate with its new internal digital layer, enabling a more efficient and autonomous customer acquisition process. This engagement marks one of Sapiens’ fastest CoreSuite implementations, reinforcing the insurer’s commitment to modernization.

By selecting Sapiens, the insurer gains a highly configurable solution that enhances product agility, streamlines operations, and empowers them to respond swiftly to evolving market demands. The seamless integration of Sapiens CoreSuite for Life & Annuities, Sapiens DataSuite, and Sapiens Cloud Services will provide the insurer with powerful, actionable data-driven insights into both agent and customer behavior, laying the groundwork for predictive analytics and improved business retention strategies.

“Sapiens’ longstanding relationship with this valued client demonstrates the trust and confidence we have built over the years,” said Roni Al-Dor, Sapiens President and CEO. “By leveraging Sapiens’ end-to-end, digital insurance platform, they can achieve full autonomy in managing their operation, enhancing operational efficiency, and delivering a superior experience for their agents and customers.”

Sapiens Insurance Platform is an AI-based, open, integrated platform that accelerates adoption, delivers sustained value, and empowers insurers to grow, modernize, and optimize for the full end-to-end insurance value chain.

Sapiens CoreSuite for Life & Annuities is a comprehensive, configurable and unified underwriting, policy, billing, and claims software to accelerate insurance transformation across all Life & Annuities business lines.

Sapiens DataSuite is a data management solution that empowers insurers to produce actionable insights and maximize the value of their data resulting in smarter decision making. DataSuite is a modular, highly innovative, business intelligence solution designed specifically for insurance markets.

Sapiens Cloud Services support business growth with elastic scaling and a holistic offering of value-added cloud services that provides all operations and application management services under one roof.

Advertisement

About Sapiens

Sapiens International Corporation (NASDAQ and TASE: SPNS) is a global leader in intelligent insurance SaaS-based software solutions. With Sapiens’ robust platform, customer-driven partnerships, and rich ecosystem, insurers are empowered to future-proof their organizations with operational excellence in a rapidly changing marketplace. Our SaaS-based Solutions help insurers harness the power of AI and advanced automation to support core solutions for property and casualty, workers’ compensation, and life insurance, including reinsurance, financial & compliance, data & analytics, digital, and decision management. Sapiens boasts a longtime global presence, serving over 600 customers in more than 30 countries with its innovative offerings. Recognized by industry experts and selected for the Microsoft Top 100 Partner program, Sapiens is committed to partnering with our customers for their entire transformation journey and is continuously innovating to ensure their success. 

For more information visit https://sapiens.com or follow us on LinkedIn  

Investor and Media Contact 
Yaffa Cohen-Ifrah 
Sapiens Chief Marketing Officer and Head of Investor Relations
Email: Yaffa.cohen-ifrah@sapiens.com

Forward Looking Statements

Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; the global macroeconomic environment, including headwinds caused by inflation, relatively high interest rates, potentially unfavorable currency exchange rate movements, and uncertain economic conditions, and their impact on our revenues, profitability and cash flows; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the coronavirus epidemic,  and fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, to be filed in the near future, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/sapiens-life-platform-selected-by-a-leading-us-insurer-302415529.html

KANSAS CITY, Mo., March 31, 2025 /PRNewswire/ — Lockton, the world’s largest independent insurance brokerage, has announced today the unification of its U.S.-based Lockton Financial Services (LFS) and International ProFin teams under a single, global practice: Lockton Professional and Executive Risk.

This strategic integration brings together the expertise of more than 750 talented Associates worldwide into a single platform designed to further enrich Lockton’s ability to create and deliver best-in-class client value.

The new structure supports what Lockton has always done best—go beyond traditional insurance offerings by delivering an insurance and risk management experience that brings a truly global perspective. With greater global connectivity, Lockton Professional and Executive Risk will help clients address their professional, executive, financial, and cyber risks no matter where they operate.

“In today’s complex and interconnected environment, companies and their boards require a trusted partner that sees their risk holistically,” said Devin Beresheim, Executive Vice President and U.S. Head of Professional and Executive Risk at Lockton. “Lockton Professional and Executive Risk delivers tailored solutions to help corporate boards and C-suite executives proactively mitigate their most pressing risks on a global level, so they can focus on growing their business.”

“Through our globally connected team, we can ensure even broader knowledge sharing, deeper risk insights, and the ability to anticipate emerging threats with greater response and precision,” said Leo Flindall, U.K. Head of Professional and Executive Risk at Lockton. “The launch of this unified team is another milestone for Lockton, reflecting our commitment to continually improving our standard for client service.”

Lockton Professional and Executive Risk serves clients across a range of industries, delivering global insurance broking, risk advisory, and claims support for all major financial and professional insurance lines. Areas of expertise include directors and officers liability, cyber, general partnership liability, errors and omissions/professional indemnity, employment practices liability, fidelity/crime, fiduciary liability, insurance solutions for digital assets.

About Lockton

What makes Lockton stand apart is also what makes us better: independence. Lockton’s private ownership empowers its 12,500+ Associates doing business in over 140 countries to focus solely on clients’ risk, insurance and people needs. With expertise that reaches around the globe, Lockton delivers deep industry knowledge and product specialization with a passion for serving clients.

Logo – https://mma.prnewswire.com/media/2342384/Lockton_70_mm_Black_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lockton-launches-professional-and-executive-risk-transforming-its-global-financial-lines-business-302415279.html

Advertisement